OQROSign up free
Politician trade (House)

Pfizer (PFE): Rep. Kathy E. Manning (NC06) disclosed a sale $15K–$50K

Rep. Kathy E. Manning (NC06) disclosed a sale of Pfizer in the $15K–$50K range.

$15,001–$50,000
Reported range · official band, not an exact amount
31 days
Disclosure lag
Traded
Dec 12, 2023
Disclosed
Jan 12, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 26, 2023CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  2. Oct 24, 2023CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  3. Dec 11, 2023CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  4. Dec 12, 2023 · this disclosureCongressDisclosed sale of PFE — reported range $15,001 - $50,000

What came next

  1. Dec 12, 2023Congress · 1 personMembers of Congress: 2 sales
  2. Dec 14, 2023FDAFDA drug approval: Cibinqo
  3. Dec 14, 2023CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  4. Dec 18, 2023CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  5. Dec 20, 2023CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  6. Dec 21, 2023FDARecall: 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous Use, Rx Only, 10 mL Syringe per Carton, Ho…
  7. Dec 21, 2023FDARecall: Bleomycin for Injection, USP, 15 units per vial, 1 single dose glass fliptop vial, Rx Only, Distributed by: Hospira, Inc., Lake Forest, IL 68045, NDC 61703-332…
  8. Dec 21, 2023FDARecall: 8.4 % Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL), Lifeshield, Glass ABBOJECT Unit of Use Syringe, Rx Only, 50 mL Syringe per Carton, Hospira, In…
  9. Dec 21, 2023FDARecall: Atropine Sulfate Injection, USP 1 mg/10 mL (0.1 mg/mL), Lifeshield, Glass ABBOJECT Unit of Use Syringe, Rx Only, 10 mL Syringe per Carton, Hospira, Inc., Lake…
  10. Dec 28, 2023Congress · 1 personMembers of Congress: 2 sales
  11. Feb 12, 2024CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  12. Feb 27, 2024CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  13. Mar 6, 2024FDAFDA drug approval: Besponsa
  14. Mar 7, 2024FDAFDA drug approval: Talzenna
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Pfizer

OQRO holds no insider, Congress, fund or contract record for Pfizer dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Rep. Kathy E. Manning (NC06)

The full history of Rep. Kathy E. Manning (NC06) is on the profile page.

How this filing works

Explore the data

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data